BE444419A - - Google Patents
Info
- Publication number
- BE444419A BE444419A BE444419DA BE444419A BE 444419 A BE444419 A BE 444419A BE 444419D A BE444419D A BE 444419DA BE 444419 A BE444419 A BE 444419A
- Authority
- BE
- Belgium
- Prior art keywords
- weight
- parts
- acid
- solution
- water
- Prior art date
Links
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 29
- 239000002253 acid Substances 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- 229960002477 riboflavin Drugs 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 150000003839 salts Chemical class 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 159000000000 sodium salts Chemical class 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 150000007530 organic bases Chemical class 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- 241000218215 Urticaceae Species 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001346 alkyl aryl ethers Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000012928 buffer substance Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000000250 methylamino group Chemical class [H]N(*)C([H])([H])[H] 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE444419A true BE444419A (OSRAM) |
Family
ID=101079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE444419D BE444419A (OSRAM) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE444419A (OSRAM) |
-
0
- BE BE444419D patent/BE444419A/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bonser et al. | The carcinogenic properties of 2-amino-1-naphthol hydrochloride and its parent amine 2-naphthylamine | |
| JPS62230897A (ja) | 液体過酸化水素／過酸水素の先駆体漂白剤 | |
| EP0263861A1 (fr) | Sel de lysine du complexe gadolinium-dota et ses applications au diagnostic. | |
| RU2002132187A (ru) | Жидкие препаративные формы | |
| FI63432C (fi) | Preparat bestaoende av lignosulfonater | |
| BE444419A (OSRAM) | ||
| CN110772508A (zh) | 一种广谱抗菌剂及其制备方法 | |
| CN112471170B (zh) | 一种草甘膦异丙胺盐水剂助剂 | |
| BE897664A (fr) | Procede de dispersion de l'hydroxypropyl methyl cellulose | |
| FI64668B (fi) | Dispersion foer anvaendning vid framstaellning av cellulosa | |
| EP0231714A1 (fr) | Compositions nématicides et insecticides à base de composés hétérocycliques | |
| KR900004928B1 (ko) | 제초력이 있는 신규 2-옥시아미노 알킬리덴-시클로헥산-1,3-디온유도체 및 그 제조방법 | |
| BE897980A (fr) | Procede pour la preparation d'une solution a usage pharmaceutique contenant un nouveau complexe mixte polynuclaire de fer (iii) comme ingredient actif | |
| KUTSUMI et al. | Effect of thiabendazole as an ovicide on helminth eggs in nightsoil | |
| RU2253153C1 (ru) | Способ моделирования хронической токсической нефропатии | |
| FR2559646A1 (fr) | Procede de reduction du taux de lignine dans les vegetaux et nouvelles compositions pour sa mise en oeuvre | |
| Ross | The tumour growth inhibitory activity of some sulphur mustard gas derivatives | |
| SU400578A1 (ru) | Способ получения растворимых форм | |
| DE110175C (OSRAM) | ||
| King | CXXI.—Derivatives of sulphur in commercial salvarsan. Part I | |
| DE607291C (de) | Herstellung loeslicher Verbindungen der Sulfamidsaeure mit Quecksilber und Alkalimetallen | |
| JPS58162560A (ja) | 酸性消炎鎮痛薬のカルシウム塩及びその坐剤 | |
| Aziz et al. | The Chelating Power of Ambilhar with Body Iron | |
| BE501332A (OSRAM) | ||
| SUZUKA et al. | Effect of diethyl maleate and sodium salicylate on cefmetazole transport in the in vitro rat everted intestinal sac: influence of Ca2+ and vanadate in the media |